10:56 AM EDT, 04/29/2024 (MT Newswires) -- AIM ImmunoTech ( AIM ) said Monday that the safety evaluation of patients in the first dose level of a phase 1b/2 trial of the combination of Ampligen, or rintatolimod, and AstraZeneca's ( AZN ) Imfinzi, or durvalumab, in late-stage pancreatic cancer has been completed.

The evaluation, conducted by investigators at Erasmus Medical Center in the Netherlands, showed that the drug combination was generally well-tolerated with no severe adverse events or dose-limiting toxicities, the company said.

The company added that the study will now move on to the next dose, with the next group of patients expected to start dosing very soon.

Shares of AIM ImmunoTech ( AIM ) fell past 4% and AstraZeneca ( AZN ) was down 4% up in recent trading activity.

Price: 0.41, Change: -0.02, Percent Change: -4.20